ArchiMed
ArchiMed is an independent asset management company founded in 2014 with offices in New York, Lyon, Singapore and Tokyo that acts as a strategic and financial partner to European and US companies in the healthcare industries.
ArchiMed has over 180 staff members, including investors and former healthcare professionals. It has raised five funds focusing on growth buyout strategies in the smallcap (MED) and mid-cap (MED Platform) segments.
- Investment date
- 2018
Peugeot Invest's investment
In 2018, Peugeot Invest committed to invest up to €80 million, with the potential to double its exposure to companies of its choosing, taking its maximum commitment to €160 million. In 2021, Peugeot Invest made a commitment of €15 million to MED III. In 2022, Peugeot Invest made a commitment of €100 million to MED Platform II.
In 2021, Peugeot Invest committed to co-invest a further €42 million (including €10 million in Bomi, which has since been sold), across four of the fund’s platforms (Bomi, Carso, Prollenium and Suanfarma). In 2022, an additional commitment of €10 million was to Natus.
In 2023
The management company continued to expand with the opening of a new office in Tokyo, and continued to increase the resources deployed to accelerate the development of its portfolio companies.
By the end of 2023, MED Platform I had raised €1 billion (2018 vintage) and had invested in seven platforms and sold one of its investments: Bomi Group (a leading European provider of specialist contract logistics for medical equipment manufacturers: investment made in 2019 and sold in 2022 for a return of 4.0x), Direct Healthcare Group (a leading European provider of specialist hospital equipment for the prevention and treatment of pressure ulcers, investment made in late 2019), NAMSA (a worldleading contract research provider to medical equipment manufacturers, investment made in 2020), Stragen (a pharmaceuticals company specialising in complex generic drugs in niche markets, investment made in 2021), Prollenium (producer of medical aesthetic products specialising in cutaneous injections of hyaluronic acid, investment made in 2021), Suanfarma (producer and distributor of pharmaceutical and nutraceutical products, investment made in 2021) and Carso (joint leader in the French testing services market, investment made in 2021).
MED Platform II had raised €2.8 billion and investedin three companies by the end of 2023: Natus (a US company specialising in neurodiagnostic equipment), PlasmidFactory (a German plasmid manufacturer involved in the production of messenger RNA vaccines and in gene and cell therapy), and Instem (a UK company supplying software and services used in drug development).
By the end of 2023, MED III (€650 million, 2021 vintage) was invested in five companies.
Alongside its commitments to the funds, Peugeot Invest invested in Polyplus together with ArchiMed and Warburg Pincus, whose sale to Sartorius in 2023 generated a net multiple of 3.8x.